Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D2.471 - Efficacy of omalizumab in the treatment of chronic spontaneous urticaria in children
D2.473 - Omalizumab as adjuvant therapy in drug desensitization to chemotherapy- a single Center experience
D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study
D2.464 - Stapokibart (anti–IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid
D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients
D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab
D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case
D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study
D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey
D2.470 - Potential Clinical and Laboratory Biomarkers for Predicting Omalizumab Response in Chronic Spontaneous Urticaria
D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation
D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report
D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months
D3.01 - Association between allergen-related antibodies and clinical phenotypes of IgG4-related disease (IgG4-RD)
D3.02 - A Well-Established Drug and A Rare Reaction: Successful Desensitization to Adalimumab
D3.04 - Sensitization Pattern and Characteristics of IgE Repertoire in Allergic Children with Excessively High Serum IgE Levels
D3.13 - Molecular characterization of food allergens in a case of suspected honey and mustard allergy
D3.14 - IgE sensitisation to parvalbumin, Ani s 1, tropomyosin and arginine kinase delineates distinct molecular endotypes of seafood allergy
D3.03 - Titanium allergy – from anamnesis to diagnosis
D3.06 - Comparative Evaluation of Raw, Blanched, Individual and Composite Allergen Preparation for Basophil Activation Testing
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download